{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:01:18Z","timestamp":1648969278409},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.cger.2005.02.004","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:50:48Z","timestamp":1118807448000},"page":"577-588","source":"Crossref","is-referenced-by-count":5,"title":["Iatrogenic Rheumatic Syndromes in the Elderly"],"prefix":"10.1016","volume":"21","author":[{"given":"G. Andres","family":"Quiceno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Cush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cger.2005.02.004_bib1","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.cger.2005.02.004_bib2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","article-title":"Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"147","author":"Jamal","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cger.2005.02.004_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk of myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.cger.2005.02.004_bib4","first-page":"973","article-title":"Do statins cause myopathy?","volume":"52","author":"Daugird","year":"2003","journal-title":"J Fam Pract"},{"key":"10.1016\/j.cger.2005.02.004_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NIHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cger.2005.02.004_bib6","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1345\/aph.1C097","article-title":"Myopathy due to statin\/fibrate use in the Netherlands","volume":"36","author":"Mantel-Teeuwise","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.cger.2005.02.004_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist","year":"2001","journal-title":"Epidemiology"},{"issue":"11","key":"10.1016\/j.cger.2005.02.004_bib8","first-page":"1237","article-title":"Safety profile of statins","volume":"129","author":"Prieto","year":"2001","journal-title":"Rev Med Chil"},{"issue":"9","key":"10.1016\/j.cger.2005.02.004_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002018-200225090-00004","article-title":"Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all the statins the same?","volume":"25","author":"Evans","year":"2002","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.cger.2005.02.004_bib10","first-page":"309","article-title":"Rhabdomyolisis and acute renal failure secondary to statins","volume":"21","author":"Borrego","year":"2001","journal-title":"Nefrologia"},{"issue":"6","key":"10.1016\/j.cger.2005.02.004_bib11","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1203\/00006450-199606000-00016","article-title":"Differen effects of 3-hydroxy-3methylgluaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats","volume":"39","author":"Reineveld","year":"1996","journal-title":"Pediatr Res"},{"issue":"5","key":"10.1016\/j.cger.2005.02.004_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"10.1016\/j.cger.2005.02.004_bib13","first-page":"72","article-title":"Mechanism of action and biological profile of HMG CoA reductase inhibitors","volume":"36","author":"Slater","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.cger.2005.02.004_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insights into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmachol Ther"},{"issue":"1","key":"10.1016\/j.cger.2005.02.004_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1567-5688(02)00002-8","article-title":"Pharmacological interactions of statins","volume":"3","author":"Paoiletti","year":"2002","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"10.1016\/j.cger.2005.02.004_bib16","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1211\/002235703765951401","article-title":"Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis","volume":"55","author":"Matzno","year":"2003","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"10.1016\/j.cger.2005.02.004_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatinine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cger.2005.02.004_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11883-003-0079-x","article-title":"Statin and myotoxicity","volume":"5","author":"Farne","year":"2003","journal-title":"Curr Atheroscler Rep"},{"issue":"2A","key":"10.1016\/j.cger.2005.02.004_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1590\/S0004-282X2004000200013","article-title":"Statin and fibrate associated myopathy: study of eight patients","volume":"62","author":"Carvalho","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.cger.2005.02.004_bib20","series-title":"Practice of geriatrics","first-page":"430","article-title":"Drug induced lupus. Musculoskeletal disorders","author":"Calkins","year":"1998"},{"issue":"5","key":"10.1016\/j.cger.2005.02.004_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.berh.2004.05.006","article-title":"Drug-induced autoimmunity","volume":"18","author":"Olsen","year":"2004","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.cger.2005.02.004_bib22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00296-003-0356-6","article-title":"Drug-induced lupus erythematosus secondary to nafcillin: the first reported case","volume":"24","author":"Blazes","year":"2004","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.cger.2005.02.004_bib23","series-title":"Primer on the rheumatic diseases","first-page":"345","article-title":"Drug-related Lupus","author":"Buyon","year":"2001"},{"key":"10.1016\/j.cger.2005.02.004_bib24","series-title":"Practical guide to the care of the medical patient","first-page":"810","article-title":"Systemic Lupus Erythematosus","author":"Ferri","year":"2004"},{"issue":"3","key":"10.1016\/j.cger.2005.02.004_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF03259997","article-title":"Drug-induced rheumatic syndromes. Diagnosis, clinical features and management","volume":"4","author":"Cohen","year":"1989","journal-title":"Med Toxicol Adverse Drug Exp"},{"issue":"3","key":"10.1016\/j.cger.2005.02.004_bib26","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.48.3.232","article-title":"Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies","volume":"48","author":"Asherson","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.cger.2005.02.004_bib27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0161-6420(89)32941-1","article-title":"Scleritis as the presenting manifestation of procainamide-induced lupus","volume":"96","author":"Turgeon","year":"1989","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.cger.2005.02.004_bib28","first-page":"51","article-title":"Lichen planus following procainamide-induced lupus erythematosus","volume":"42","author":"Sherertz","year":"1988","journal-title":"Cutis"},{"issue":"2","key":"10.1016\/j.cger.2005.02.004_bib29","first-page":"375","article-title":"Laryngeal manifestations of drug induced lupus","volume":"14","author":"Maxwell","year":"1987","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.cger.2005.02.004_bib30","first-page":"12","article-title":"Adverse immunological effects of antithyroid drugs","volume":"136","author":"Wing","year":"1987","journal-title":"CMAJ"},{"key":"10.1016\/j.cger.2005.02.004_bib31","series-title":"Rheumatology diagnosis and therapeutics","first-page":"193","article-title":"Drug-induced lupus","author":"Cush","year":"1999"},{"issue":"2","key":"10.1016\/j.cger.2005.02.004_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.1780280209","article-title":"The diagnostic value of antihistone antibodies in drug-induced lupus erythematosus","volume":"28","author":"Epstein","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.cger.2005.02.004_bib33","first-page":"2157","article-title":"Antihistone antibody profile in sufasalazine induced lupus","volume":"21","author":"Bray","year":"1994","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.cger.2005.02.004_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002281-199909000-00006","article-title":"Etiology and mechanism of drug-induced lupus","volume":"11","author":"Rubin","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cger.2005.02.004_bib35","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0149-2918(03)80158-3","article-title":"A literature review of the epidemiology and treatment of acute gout","volume":"25","author":"Kim","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.cger.2005.02.004_bib36","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1001\/jama.289.21.2857","article-title":"Gout","volume":"289","author":"Rott","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2005.02.004_bib37","series-title":"Rheumatology: diagnosis and therapeutics","first-page":"187","article-title":"Gout","author":"Cush","year":"2005"},{"issue":"5","key":"10.1016\/j.cger.2005.02.004_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1345\/aph.1A288","article-title":"Colchicine-induced rhabdomyolysis","volume":"36","author":"Boomershine","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.cger.2005.02.004_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1345\/aph.1A124","article-title":"Cutaneous and systemic manifestations of drug-induced vasculitis","volume":"36","author":"ten Holder","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.cger.2005.02.004_bib40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/14740338.2.4.401","article-title":"Drug-induced vasculitis","volume":"2","author":"Doyle","year":"2003","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069005000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T17:57:33Z","timestamp":1548439053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069005000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0749069005000078"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2005.02.004","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}